TCRX
TScan Therapeutics Inc.
NASDAQ · Healthcare
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 10.3M | 2.8M | 21.0M | 13.5M | 10.1M | 1.1M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Expenses | ||||||
| R&D Expenses | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — |
| Operating Income | -135.8M | -134.8M | -93.5M | -66.6M | -48.6M | -26.2M |
| EBITDA | — | — | — | — | — | — |
| Below the Line | ||||||
| Interest Expense | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — |
| Net Income | -129.8M | -127.5M | -89.2M | -66.2M | -48.6M | -26.1M |
| Per Share | ||||||
| EPS (basic) | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — |
| Shares | ||||||
| Basic Shares | — | — | — | — | — | — |
| Diluted Shares | 130M | 112M | 66M | 24M | 12M | 1M |